KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Capital Expenditures (2016 - 2026)

Bristol Myers Squibb has reported Capital Expenditures over the past 18 years, most recently at $347.0 million for Q1 2026.

  • Quarterly Capital Expenditures rose 33.46% to $347.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Mar 2026, up 14.22% year-over-year, with the annual reading at $1.3 billion for FY2025, 5.05% up from the prior year.
  • Capital Expenditures was $347.0 million for Q1 2026 at Bristol Myers Squibb, down from $370.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $378.0 million in Q4 2024 and troughed at $247.0 million in Q3 2022.
  • The 5-year median for Capital Expenditures is $320.0 million (2025), against an average of $307.8 million.
  • The largest YoY upside for Capital Expenditures was 46.24% in 2022 against a maximum downside of 8.52% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $346.0 million in 2022, then decreased by 4.62% to $330.0 million in 2023, then increased by 14.55% to $378.0 million in 2024, then decreased by 2.12% to $370.0 million in 2025, then dropped by 6.22% to $347.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Capital Expenditures are $347.0 million (Q1 2026), $370.0 million (Q4 2025), and $320.0 million (Q3 2025).